NRAS G12C
Clinical trials for NRAS G12C explained in plain language.
Never miss a new study
Get alerted when new NRAS G12C trials appear
Sign up with your email to follow new studies for NRAS G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New immunotherapy targets tough pancreatic cancers in early trial
Disease control OngoingThis early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…
Matched conditions: NRAS G12C
Phase 1/2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New immunotherapy option for High-Risk pancreatic cancer patients
Disease control Expanded access (ended)This expanded access program offers ELI-002 7P, an immunotherapy, to pancreatic cancer patients with specific KRAS or NRAS gene mutations who have had their tumor removed but are at high risk of the cancer coming back. The treatment aims to stimulate the immune system to target a…
Matched conditions: NRAS G12C
Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC